Anabella Villalobos

Short description: Medicinal chemist

Anabella Villalobos

Alma mater| University of Panama, B.S. in Chemistry
University of Kansas, PhD in Medicinal chemistry
Scientific career
Fields| Medicinal chemistry
Institutions|

* Yale University as NIH Postdoctoral Fellow
* Pfizer}Biogen

Anabella P. Villalobos is a medicinal chemist and senior pharmaceutical executive at Biogen.[1]

## Background and career

Villalobos was raised in Panama City. She received her BS in chemistry from the University of Panama, received her Ph.D. (1987) at the University of Kansas with Professor Lester A. Mitscher, and was a National Institutes of Health postdoctoral fellow at Yale University, working with Samuel J. Danishefsky.[1][2] She joined Pfizer in 1989, working on a variety of Central nervous system (CNS) projects in medicinal chemistry,[3] diagnostics, and Positron emission tomography imaging radiotracers against Alzheimer's disease.[4][5] In 2001, Villalobos became Head of CNS Medicinal Chemistry, and in 2007 Head of Antibacterial and CNS Chemistry.[6] By 2016, she was VP of Neuroscience and Pain medicinal chemistry, and published a video outreach campaign to describe her work.[7] In 2017, Villalobos was recruited to be the Senior Vice President for Biotherapeutics & Medicinal Sciences at Biogen.[1]

## Awards and honors

* 2014: Connecticut Women's Hall of Fame honoree[8]
* 2010: CURE award for neuroscience research[9]
* 1987-1989: NIH postdoctoral fellow[citation needed]
* 1981-1983: Fulbright-Hays fellow[2]

## References

1. ↑ 1.0 1.1 1.2 "Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences" (in en). https://www.businesswire.com/news/home/20170731005551/en/Biogen-Appoints-Anabella-Villalobos-Senior-Vice-President.
2. ↑ 2.0 2.1 "Villalobos, Anabella" (in en). https://www.acs.org/content/acs/en/acs-webinars/presenters/anabella-villalobos.html.
3. ↑ Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella (2016-06-15). "Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery". ACS Chemical Neuroscience 7 (6): 767–775. doi:10.1021/acschemneuro.6b00029. PMID 26991242.
4. ↑ Zhang, Lei; Chen, Laigao; Dutra, Jason K.; Beck, Elizabeth M.; Nag, Sangram; Takano, Akihiro; Amini, Nahid; Arakawa, Ryosuke et al. (2018-04-26). "Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain". Journal of Medicinal Chemistry 61 (8): 3296–3308. doi:10.1021/acs.jmedchem.7b01769. ISSN 0022-2623. PMID 29356535.
5. ↑ "Clinical-Stage Biotech Developing Treg-based Therapies" (in en-US). https://coyatherapeutics.com/about-us/.
6. ↑ "Professor Robin Zavod, PhD, 1992, University of Kansas" (in en). https://studylib.net/doc/8484006/professor-robin-zavod--phd--1992--university-of-kansas.
7. ↑ Villalobos, Anabella (2016). "What We're Working On". https://www.youtube.com/watch?v=pAb5i3YtGEw.
8. ↑ "Connecticut Women's Hall of Fame to Honor Niantic's Anabella Villalobos" (in en). 2014-10-23. https://patch.com/connecticut/thelymes/connecticut-womens-hall-fame-honor-niantics-anabella-villalobos.
9. ↑ "Alzheimer's research wins award for Pfizer". https://www.pressreader.com/usa/the-day/20100427/281762740463886.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Anabella Villalobos. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Anabella_Villalobos&oldid=296288"